Impact of lymphopenia on efficacy of nivolumab in head and neck cancer patients

[1] Pignon J-P(2009)Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol J Eur Soc Ther Radiol Oncol 92 4-14

[2] le Maître A(2017)Distant metastases in head and neck cancer Head Neck 39 1733-1743

[3] Maillard E(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454

[4] Duprez F(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-1867

[5] Berwouts D(2019)Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet Lond Engl 394 1915-1928

[6] De Neve W(2019)Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142) J Clin Oncol 37 6060-6060

[7] Topalian SL(2018)Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas J Immunother Cancer 6 84-2608

[8] Hodi FS(2017)Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers Mol Cancer Ther 16 2598-1611

[9] Brahmer JR(2017)Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ann Oncol Off J Eur Soc Med Oncol 28 1605-1753

[10] Ferris RL(2020)Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer Int J Clin Oncol 36 1747-7

[1] Pignon J-P(2009)Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol J Eur Soc Ther Radiol Oncol 92 4-14

[2] le Maître A(2017)Distant metastases in head and neck cancer Head Neck 39 1733-1743

[3] Maillard E(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2454

[4] Duprez F(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-1867

[5] Berwouts D(2019)Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet Lond Engl 394 1915-1928

[6] De Neve W(2019)Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142) J Clin Oncol 37 6060-6060

[7] Topalian SL(2018)Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas J Immunother Cancer 6 84-2608

[8] Hodi FS(2017)Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers Mol Cancer Ther 16 2598-1611

[9] Brahmer JR(2017)Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Ann Oncol Off J Eur Soc Med Oncol 28 1605-1753

[10] Ferris RL(2020)Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer Int J Clin Oncol 36 1747-7